0000950170-23-068795.txt : 20231207
0000950170-23-068795.hdr.sgml : 20231207
20231207160517
ACCESSION NUMBER: 0000950170-23-068795
CONFORMED SUBMISSION TYPE: 3
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20231130
FILED AS OF DATE: 20231207
DATE AS OF CHANGE: 20231207
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Higgins Michael J
CENTRAL INDEX KEY: 0001478521
FILING VALUES:
FORM TYPE: 3
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38787
FILM NUMBER: 231472378
MAIL ADDRESS:
STREET 1: C/O GENOCEA BIOSCIENCES, INC.
STREET 2: 100 ACORN PARK DRIVE, 5TH FLOOR
CITY: CAMBRIDGE
STATE: MA
ZIP: 02140
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Cyclerion Therapeutics, Inc.
CENTRAL INDEX KEY: 0001755237
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 831895370
STATE OF INCORPORATION: MA
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 301 BINNEY STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
BUSINESS PHONE: 617-621-7722
MAIL ADDRESS:
STREET 1: 301 BINNEY STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
3
1
ownership.xml
3
X0206
3
2023-11-30
0
0001755237
Cyclerion Therapeutics, Inc.
CYCN
0001478521
Higgins Michael J
C/O CYCLERION THERAPEUTICS, INC.
245 FIRST STREET, 18TH FLOOR
CAMBRIDGE
MA
02142
true
false
false
false
Common Stock
21650
D
Prior to becoming a Reporting Person, Mr. Higgins held 1,650 shares of common stock of Cyclerion Therapeutics, Inc. On November 30, 2023, the Reporting Person was granted 20,000 shares of restricted stock pursuant to the Cyclerion Therapeutics, Inc. 2019 Equity Incentive Plan, of which 2,500 of these shares vest immediately and the remaining 17,500 shares vest ratably over a 42-month period, provided that the Reporting Person remains as a director of Cyclerion Therapeutics, Inc. on such applicable vesting date, subject to certain exemptions.
/s/ Michael Higgins
2023-12-07